MotorWeek goes full speed ahead into an unprecedented 44th season equipped with a shiny new app
August 22, 2024 11:43 ET
|
Maryland Public Television
OWINGS MILLS, MD, Aug. 22, 2024 (GLOBE NEWSWIRE) -- MotorWeek keeps the throttle pinned for a 44th season of television’s original and longest-running automotive video magazine series. The new...
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication
August 20, 2024 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department More than 27,569 individuals in the U.S. died from drug overdose...
Payments Trends to Watch in H2 2024: Wallets Enable Commerce, Credit Cards Face New BNPL Threat and Physical Cards Fade Away
August 09, 2024 04:30 ET
|
Research and Markets
Dublin, Aug. 09, 2024 (GLOBE NEWSWIRE) -- The "Payments Trends to Watch in H2 2024" report has been added to ResearchAndMarkets.com's offering. Accelerating payments innovation is transforming...
Choline Chloride Global Strategic Research Report 2024: Market to Reach $1.4 Billion by 2030 - Need to Increase Meat Production Puts the Market in Overdrive
June 17, 2024 10:13 ET
|
Research and Markets
Dublin, June 17, 2024 (GLOBE NEWSWIRE) -- The "Choline Chloride - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Choline Chloride...
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
June 14, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and...
Deposco Garners 2024 SupplyTech Breakthrough Award For “3PL Innovation Of The Year”
June 13, 2024 08:02 ET
|
SupplyTech Breakthrough
LOS ANGELES, June 13, 2024 (GLOBE NEWSWIRE) -- SupplyTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout technology companies, products...
AGBA/Triller $4bn Merger: The Group files its Preliminary Proxy Statement
June 12, 2024 08:20 ET
|
AGBA Group Holding Ltd
LOS ANGELES, June 12, 2024 (GLOBE NEWSWIRE) -- NASDAQ-listed, AGBA Group Holding Limited (“AGBA” or the “Company” or the “Group”), reports that on June 12, 2024, the company filed its preliminary...
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
June 03, 2024 12:00 ET
|
Crinetics Pharmaceuticals, Inc.
100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg) CAH Participants Achieved More Than a 90% Reduction of...
Overland AI Secures $10M in Seed Funding to Accelerate Development of Autonomous Vehicle Software for High-Risk Missions
May 20, 2024 12:00 ET
|
Overland AI
SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Overland AI, a Seattle-based pioneer in off-road ground vehicle autonomy for the defense sector, today announced it has secured $10 million in seed funding,...
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
May 14, 2024 10:00 ET
|
Kymera Therapeutics, Inc.
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology...